HMB study

Randomized controlled trial of b-hydroxy-b-methyl butyrate-enriched formula to improve sarcopenia after liver transplantation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1051210114

Enrollment

116

Registered

2021-10-28

Start date

2021-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled to undergo living donor liver transplantation Decompensated cirrhosis

Interventions

The nutritional supplementation (Abound

Abbott Japan Co., Tokyo, Japan) contained protein mixed Ca-HMB (1500 mg), L-arginine (7000 mg), and L-glutamine (7000 mg) per pack, and patients in the HMB group receive 2 packs per day either orally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Scheduled to undergo living donor liver transplantation at Kyoto University Hospital 20 years and over at time of registration Amenable to enteral nutrition Consents for this study Does not meet all of the exclusion criteria

Exclusion criteria

Exclusion criteria: Re-transplantation Acute liver failure History of allergy to HMB-rich nutrients Cases judged by the investigator to be inappropriate

Design outcomes

Primary

Measure	Time frame
Skeletal muscle mass index and grip strength at 1 month after living donor liver transplantation (LDLT)	—

Secondary

Measure	Time frame
Skeletal muscle mass index and grip strength at 2 months after LDLT Laboratory data Incidence of postoperative bacteremia Length of postoperative hospital stay Period of enteral nutrition Period of drainage Biopsy-proven acute cellular rejection	—

Contacts

Public ContactNaoko Kamo

Kyoto University Hospital

naoko@kuhp.kyoto-u.ac.jp+81-75-751-4323

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026